Ratings Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Real-time Estimate Cboe BZX Other stock markets 03:59:31 2024-04-29 pm EDT			5-day change	1st Jan Change
21.98 ^USD	+5.90%		+0.09%	-28.34%

Apr. 15	Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	CI
Mar. 25	Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	MT

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
INTELLIA THERAPEUTICS, INC.	-28.34%	2B	B-
IQVIA HOLDINGS INC.	+1.51%	42.75B	B
LONZA GROUP AG	+47.70%	41.61B	A
MODERNA, INC.	+12.35%	41.34B	B-
CELLTRION, INC.	-8.83%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+6.79%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.07%	18.12B	B
MEDPACE HOLDINGS, INC.	+30.06%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.33%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+8.56%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes